ALK acquires Otiprio, broadening solutions for swimmer's ear, ear tube surgery

3 June 2021

Danish allergy immunotherapy specialist ALK Abello (ALKB: DC) today announced that it has acquired Otiprio (ciprofloxacin otic suspension) from Texas, USA-based Otonomy (Nasdaq: OTIC).

Otiprio is a prescription fluoroquinolone antibacterial approved to treat pediatric patients six months of age and older with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP), and to treat acute otitis externa (AOE), also known as swimmer's ear, in patients six months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.

The acquisition, financial terms of which were not disclosed, will strengthen ALK's expansion into ear, nose and throat (ENT) and pediatrics. In June 2020, ALK signed an exclusive agreement with Otonomy for the co-promotion of Otiprio, which included exclusive rights to market the drug for AOE to office-based health care professionals in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK